<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">actabiomedica</journal-id><journal-title-group><journal-title xml:lang="ru">Acta Biomedica Scientifica</journal-title><trans-title-group xml:lang="en"><trans-title>Acta Biomedica Scientifica</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2541-9420</issn><issn pub-type="epub">2587-9596</issn><publisher><publisher-name>Scientific Centre for Family Health and Human Reproduction Problems</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.29413/ABS.2021-6.3.7</article-id><article-id custom-type="elpub" pub-id-type="custom">actabiomedica-2848</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ИНФЕКЦИОННЫЕ БОЛЕЗНИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>INFECTIOUS DISEASES</subject></subj-group></article-categories><title-group><article-title>Роль белков MRP8 (S100A8) и MRP14 (S100A9) в развитии критического состояния у больных пневмонией на фоне гриппа A/H1N1</article-title><trans-title-group xml:lang="en"><trans-title>Role of proteins MRP8 (S100A8) and MRP14 (S100A9) in the development of critical condition in patients with pneumonia with A/H1N1 influenza</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0559-797X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Малярчиков</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Malyarchikov</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p> к.м.н., заведующий кафедрой симуляционно-тренингового обучения </p><p> 672000, г. Чита, ул. Горького, 39А, Россия </p></bio><bio xml:lang="en"><p> Cand. Sc. (Med), Head of Simulation Training Department</p><p> Gorkogo str. 39A, 672090, Chita, Russian Federation </p></bio><email xlink:type="simple">malyarchikov@bk.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3485-5176</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шаповалов</surname><given-names>К. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Shаpovаlov</surname><given-names>K. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p> д.м.н., профессор, заведующий кафедрой анестезиологии, реанимации и интенсивной терапии </p><p> 672000, г. Чита, ул. Горького, 39А, Россия </p></bio><bio xml:lang="en"><p> Dr. Sc. (Med.), Professor, Head of the Department of Anesthesiology, Resuscitation and Intensive Care </p><p> Gorkogo str. 39A, 672090, Chita, Russian Federation </p></bio><email xlink:type="simple">shkg26@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7997-9116</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лукьянов</surname><given-names>С. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Lukyanov</surname><given-names>S. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p> к.м.н., доцент кафедры пропедевтики внутренних болезней </p><p> 672000, г. Чита, ул. Горького, 39А, Россия </p></bio><bio xml:lang="en"><p> Cand. Sc. (Med), Associate Professor of the Department of Propedeutics of Internal Diseases </p><p> Gorkogo str. 39A, 672090, Chita, Russian Federation </p></bio><email xlink:type="simple">lukyanov-sergei@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9816-9714</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Казанцева</surname><given-names>Л. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Kazantseva</surname><given-names>L. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p> соискатель кафедры анестезиологии, реанимации и интенсивной терапии </p><p> 672000, г. Чита, ул. Горького, 39А, Россия </p></bio><bio xml:lang="en"><p> Applicant for the Department of Anesthesiology, Resuscitation and Intensive Care </p><p> Gorkogo str. 39A, 672090, Chita, Russian Federation </p></bio><email xlink:type="simple">mila-kazantseva93@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБОУ ВО «Читинская государственная медицинская академия» Минздрава России</institution></aff><aff xml:lang="en"><institution>Chita State Medical Academy </institution></aff></aff-alternatives><pub-date pub-type="collection"><year>2021</year></pub-date><pub-date pub-type="epub"><day>12</day><month>08</month><year>2021</year></pub-date><volume>6</volume><issue>3</issue><fpage>70</fpage><lpage>76</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Малярчиков А.В., Шаповалов К.Г., Лукьянов С.А., Казанцева Л.С., 2021</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="ru">Малярчиков А.В., Шаповалов К.Г., Лукьянов С.А., Казанцева Л.С.</copyright-holder><copyright-holder xml:lang="en">Malyarchikov A.V., Shаpovаlov K.G., Lukyanov S.A., Kazantseva L.S.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.actabiomedica.ru/jour/article/view/2848">https://www.actabiomedica.ru/jour/article/view/2848</self-uri><abstract><sec><title> Актуальность</title><p> Актуальность. Современная медицина критических состояний активно развивается, и бурный прогресс тесно связан с достижениями молекулярной биологии,  иммунологии, патологической физиологии. Изучение роли отдельных молекулярных структур в реализации реакций  врожденного и адаптивного иммунитета, лежащими в основе патогенеза критических состояний является  актуальным научным направлением и представляет интерес.</p></sec><sec><title>Цель работы</title><p>Цель работы. Оценить вклад белкового комплекса MRP-8/14 в развитие системного воспаления, определив его плазменную концентрацию у больных пневмониями на  фоне гриппа A/H1N1.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. Обследовано 85 больных с пневмонией на фоне гриппа A/H1N1. Из них 30 пациентов с тяжелой пневмонией, 55 – с нетяжелой пневмонией.  Методом проточной цитофлуометрии на анализаторе (Beckman Coulter, США) определяли плазменную  концентрацию белкового комплекса MRP-8/14 (S100A8/A9).</p></sec><sec><title>Результаты</title><p>Результаты. Установлено, что у больных тяжелой пневмонией на фоне гриппа A/H1N1 концентрация MRP-8/14 увеличивалась в 1,9 раза по сравнению со здоровыми.  При этом в группе пациентов с наступившим летальным  исходом концентрация MRP-8/14 увеличивалась в 2,1 раза.</p></sec><sec><title>Заключение</title><p>Заключение. Повышение уровня MRP-8/14 у больных тяжелой пневмонией на фоне гриппа A/H1N1, с одной стороны, отражает тяжесть течения системного воспаления,  с другой стороны, молекулы MRP-8 и MRP-14, выступая в  качестве молекулярных паттернов, ассоциированных с  повреждениями (DAMPs), стимулируют провоспалительный  ответ и вносят вклад в развитие критического состояния. В связи с этим, белковый комплекс MRP-8/14 может рассматриваться как потенциальная точка приложения  фармакологического воздействия в интенсивной терапии  критических состояний.  </p></sec></abstract><trans-abstract xml:lang="en"><sec><title> Background</title><p> Background. Today, the critical care medicine is actively developing, and rapid progress is closely related to the achievements of molecular biology, immunology, and pathological physiology. The study of the role of individual molecular structures in the realization of the reactions of innate and adaptive immunity, which underlie the pathogenesis of critical conditions, is an urgent scientific direction and is of interest.</p></sec><sec><title>Aims</title><p>Aims. To assess the contribution of the protein complex MRP-8/14 to thedevelopment of systemic inflammation by determining its plasma  concentration in patients with pneumonia with influenza A/H1N1.</p></sec><sec><title>Materials and methods</title><p>Materials and methods. 85 patients with pneumonia associated with influenza A/H1N1 were examined. Of these, 30 patients with severe pneumonia, 55 with non-severe pneumonia. The plasma concentration of the S100A8/A9 protein complex (MRP-8/14) was determined by flow cytometry on an analyzer (Beckman Coulter, USA).</p></sec><sec><title>Results</title><p>Results. It was found that in patients with severe pneumonia with influenza A/H1N1, the concentration of MRP-8/14 increased in 1.9 times compared  with healthy. At the same time, in patients with severe pneumonia with influenza A/H1N1 with a fatal outcome, the concentration of MRP-8/14 increased in 2.1 times.</p></sec><sec><title>Conclusion</title><p>Conclusion. An increase in the level of MRP-8/14 in patients with severe pneumonia associated with influenza A/H1N1, on the one hand, reflects the severity of the course of systemic inflammation, on the other hand, the molecules MRP-8 and MRP-14, acting as damage-associated molecular patterns (DAMPs) stimulate a pro-inflammatory response and contribute to the development of critical state. Thereby, the protein complex MRP-8/14 can be considered as a potential point of application of pharmacological action in the intensive care of critical conditions. </p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>Кальпротектин</kwd><kwd>MRP-8/14</kwd><kwd>грипп A/H1N1</kwd><kwd>пневмония</kwd><kwd>системное воспаление</kwd></kwd-group><kwd-group xml:lang="en"><kwd>Calprotectin</kwd><kwd>MRP-8/14</kwd><kwd>influenza A/H1N1</kwd><kwd>pneumonia</kwd><kwd>systemic inflammation</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Исследование выполнено при финансовом обеспечении ФГБОУ ВО «Читинская государственная медицинская академия» Минздрава России.</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Гусев Е. Ю., Черешнев В. А. Иммунологические и патофизиологические механизмы системного воспаления. Медицинская иммунология. 2012; 1–2. URL: https://cyberleninka.ru/article/n/immunologicheskie-i-patofiziologicheskie-mehanizmysistemnogo-vospaleniya. [дата обращения: 04.04.2021]</mixed-citation><mixed-citation xml:lang="en">Gusev EYu, Chereshnev VA. Immunological and pathophysiological mechanisms of systemic inflammation. Medical Immunology/Meditsinskaya Immunologiya. 2012; 1–2. URL: https://cyberleninka.ru/article/n/immunologicheskie-ipatofiziologicheskie-mehanizmy-sistemnogo-vospaleniya. [date of access: 04/04/2021]. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Гусев Е. Ю., Зотова Н. В., Лазарева М. А. Цитокиновый ответ и другие отличительные особенности критических фаз системного воспаления при сепсисе. Медицинская иммунология. 2014; 2. URL: https://cyberleninka.ru/article/n/tsitokinovyy-otvet-i-drugie -otlichitelnye -osobennostikriticheskih-faz-sistemnogo-vospaleniya-pri-sepsise. [дата обращения: 04.04.2021]</mixed-citation><mixed-citation xml:lang="en">Gusev EYu, Zotova NV, Lazareva MA. Cytokine response and other distinctive features of critical phases of systemic inflammation in sepsis. Medical Immunology/Meditsinskaya Immunologiya. 2014; 2. URL: https://cyberleninka.ru / article / n / tsitokinovyy-otvet-i-drugie-otlichitelnyeosobennosti-kriticheskih-faz-sistemnogo-vospaleniya-prisepsise [date of access: 04/04/2021]. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Насонов Е. Л, Александрова Е. Н, Новиков А. А. Аутоиммунные ревматические заболевания – проблемы иммунопатологии и персонифицированной терапии. Вестник РАМН. 2015; 70 (2): 169–82. doi: 10.15690/vramn.v70i2.1310</mixed-citation><mixed-citation xml:lang="en">Nasonov EL, Aleksandrova EN, Novikov AA. Autoimmune rheumatic diseases – problems of immunopathology and personalized therapy. Vestnik RAMN. 2015; 70 (2):169–82. doi: 10.15690/vramn.v70i2.1310. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Полушин Ю. С., Храпов К. Н., Майская М. Ю., Дикарев К. В. Вирусная пневмония гриппа А (H1N1), осложненная ОРДС. Общая реаниматология. 2010; 6 (3):15. doi.org/10.15360/1813-9779-2010-3-15</mixed-citation><mixed-citation xml:lang="en">Polushin YuS, Khrapov KN, Maiskaya MYu, Dikarev KV. Viral Pneumonia Influenza A (H1N1) Complicated by Acute Viral Respiratory Distress Syndrome. General Reanimatology. 2010;6 (3):15. doi.org/10.15360/1813-9779-2010-3-15. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Ханова М. Ю., Григорьев Е. В. Роль рецепторов PD-1 и PD–L1 в развитии системного воспалительного ответа и методы иммуноадъювантной терапии. Патология кровообращения и кардиохирургия. 2019; 23 (3): 76–83. doi.org/10.21688/1681-3472-2019-3-76-83</mixed-citation><mixed-citation xml:lang="en">Khanova MYu, Grigoryev EV. Roles of PD-1 and PD–L1 receptors in the development of systemic inflammatory response and immunoadjuvant therapy. Patologiya krovoobrashcheniya i kardiokhirurgiya. Circulation Pathology and Cardiac Surgery. 2019; 23 (3):76–83. doi.org/10.21688/1681-3472-2019-3-76-83. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Щербо С. Н. Тенденции развития и технологии современной лабораторной медицины. Лабораторная медицина. 2013; (12): 39–44</mixed-citation><mixed-citation xml:lang="en">Shcherbo SN. Development trends and technologies of modern laboratory medicine. Laboratornaya Meditsina. 2013; (12): 39–44 (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Ma Y, Fan D, Xu S, Deng J, Gao X, Guan S, et al. Calprotectin in spondyloarthritis: A systematic review and meta-analysis. Int Immunopharmacol. 2020; 88: 106948.doi: 10.1016/j.intimp.2020.106948</mixed-citation><mixed-citation xml:lang="en">Ma Y, Fan D, Xu S, Deng J, Gao X, Guan S, et al. Calprotectin in spondyloarthritis: A systematic review and metaanalysis. Int Immunopharmacol. 2020; 88: 106948. doi: 10.1016/j.intimp.2020.106948</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Simard JC, Cesaro A, Chapeton-Montes J, et al. S100A8 and S100A9 induce cytokine expression and regulate the NLRP3 inflammasome via ROS-dependent activation of NF-κB (1.). PLoS One. 2013; 8 (8):e72138. doi:10.1371/journal.pone.0072138</mixed-citation><mixed-citation xml:lang="en">Simard JC, Cesaro A, Chapeton-Montes J, et al. S100A8 and S100A9 induce cytokine expression and regulate the NLRP3 inflammasome via ROS-dependent activation of NF-κB (1.). PLoS One. 2013; 8 (8):e72138. doi:10.1371/journal.pone.0072138</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Foley Ch, MacDermott E, Killeen O. Myeloid-related proteins 8 and 14: potential biomarkers of disease activity of arthritis in children with trisomy 21. Rheumatology. 2015; 54 (2), doi.org/10.1093/rheumatology/keu521</mixed-citation><mixed-citation xml:lang="en">Foley Ch, MacDermott E, Killeen O. Myeloid-related proteins 8 and 14: potential biomarkers of disease activity of arthritis in children with trisomy 21. Rheumatology. 2015; 54 (2), doi.org/10.1093/rheumatology/keu521</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Kerkhoff C, Nacken W, Benedyk M, Dagher MC, Sopalla C, Doussiere J. The arachidonic acid-binding protein S100A8/A9 promotes NADPH oxidase activation by interaction with p67phox and Rac-2. FASEB J. 2005; 19 (3):467–9. doi: 10.1096/fj.04-2377fje</mixed-citation><mixed-citation xml:lang="en">Kerkhoff C, Nacken W, Benedyk M, Dagher MC, Sopalla C, Doussiere J. The arachidonic acid-binding protein S100A8/A9 promotes NADPH oxidase activation by interaction with p67phox and Rac-2. FASEB J. 2005; 19 (3):467–9. doi: 10.1096/fj.04-2377fje</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Coutant R, Landais P, Rosilio M, Johnsen C, Lahlou N, Chatelain P, et al. Low dose linomide in type I juvenile diabetes of recent onset: a randomised placebo-controlled double blind trial. Diabetologia. 1998; 41 (9):1040-6. doi:10.1007/s001250051028</mixed-citation><mixed-citation xml:lang="en">Coutant R, Landais P, Rosilio M, Johnsen C, Lahlou N, Chatelain P, et al. Low dose linomide in type I juvenile diabetes of recent onset: a randomized placebo-controlled double-blind trial. Diabetologia. 1998; 41 (9): 1040-6. doi: 10.1007/s001250051028</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Tsai SY, Segovia JA, Chang TH, Morris IR, Berton MT, Tessier PA, et al. DAMP molecule S100A9 acts as a molecular pattern to enhance inflammation during influenza A virus infection: role of DDX21-TRIF-TLR4-MyD88 pathway. PLoS Pathog. 2014; 10 (1):e1003848. doi: 10.1371/journal.ppat.1003848</mixed-citation><mixed-citation xml:lang="en">Tsai SY, Segovia JA, Chang TH, Morris IR, Berton MT, Tessier PA, et al. DAMP molecule S100A9 acts as a molecular pattern to enhance inflammation during influenza A virus infection: role of DDX21- TRIF-TLR4-MyD88 pathway. PLoS Pathog. 2014; 10 (1):e1003848. doi: 10.1371/journal.ppat.1003848</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Черешнев В. А., Гусев Е. Ю. Иммунологические и патофизиологические механизмы системного воспаления. Медицинская иммунология. 2012; 14 (1-2): 9–20</mixed-citation><mixed-citation xml:lang="en">Chereshnev VA, Gusev EYu. Immunologicheskie i patofiziologicheskie mekhanizmy sistemnogo vospaleniya [Immunological and pathophysiological mechanisms of systemic inflammation]. Meditsinskaya immunologiya/Medical Immunology. 2012; 14 (1–2): 9–20 (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Артемьева О. В., Ганковская Л. В. Воспалительное старение как основа возраст-ассоциированной патологии. Медицинская иммунология. 2020;22 (3): 419–432. doi.org/10.15789/1563–0625-IAT-1938</mixed-citation><mixed-citation xml:lang="en">Artemyeva OV, Gankovskaya LV. Inflammaging as the basis of age-associated diseases. Medical Immunology. 2020; 22 (3): 419–432. doi.org/10.15789/1563–0625-IAT-1938. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Liu HY, Xiang HX, Xiang Y, Xu Z, Feng CM, Fei J, et al. The associations of serum S100A9 with the severity and prognosis in patients with community-acquired pneumonia: a prospective cohort study. BMC Infect Dis. 2021; 21 (1): 327. doi: 10.1186/s12879-021-06020-y</mixed-citation><mixed-citation xml:lang="en">Liu HY, Xiang HX, Xiang Y, Xu Z, Feng CM, Fei J, Fu L, Zhao H. The associations of serum S100A9 with the severity and prognosis in patients with community-acquired pneumonia: a prospective cohort study. BMC Infect Dis. 2021; 21 (1): 327. doi: 10.1186/s12879-021-06020-y</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Mahler M, Meroni PL, Infantino M, Buhler KA, Fritzler MJ. Circulating Calprotectin as a Biomarker of COVID-19 Severity. Expert Rev Clin Immunol. 2021; 13:1–13. doi: 10.1080/1744666X.2021.1905526</mixed-citation><mixed-citation xml:lang="en">Mahler M, Meroni PL, Infantino M, Buhler KA, Fritzler MJ. Circulating Calprotectin as a Biomarker of COVID-19 Severity. Expert Rev Clin Immunol. 2021; 13:1–13. doi: 10.1080/1744666X.2021.1905526</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Udeh R, Advani S, de Guadiana Romualdo LG, DoljaGore X. Calprotectin, an Emerging Biomarker of Interest in COVID-19: A Systematic Review and Meta-Analysis. J Clin Med. 2021; 10 (4): 775. doi: 10.3390/jcm10040775</mixed-citation><mixed-citation xml:lang="en">Udeh R, Advani S, de Guadiana Romualdo LG, DoljaGore X. Calprotectin, an Emerging Biomarker of Interest in COVID-19: A Systematic Review and Meta-Analysis. J Clin Med. 2021; 10 (4): 775. doi: 10.3390/jcm10040775</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Al-Garawi A, Husain M, Ilieva D, Humbles AA, Kolbeck R, Stampfli MR, et al. Shifting of immune responsiveness to house dust mite by influenza A infection: genomic insights. J Immunol. 2012; 188 (2): 832–43. doi: 10.4049/jimmunol.1102349</mixed-citation><mixed-citation xml:lang="en">Al-Garawi A, Husain M, Ilieva D, Humbles AA, Kolbeck R, Stampfli MR, et al. Shifting of immune responsiveness to house dust mite by influenza A infection: genomic insights. J Immunol. 2012; 188 (2): 832–43. doi: 10.4049/jimmunol.1102349</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Franchi L, Eigenbrod T, Muñoz-Planillo R, Nuñez G. The inflammasome: a caspase-1-activation platform that regulates immune responses and disease pathogenesis. Nat Immunol. 2009; 10 (3): 241–7. doi: 10.1038/ni.1703</mixed-citation><mixed-citation xml:lang="en">Franchi L, Eigenbrod T, Muñoz-Planillo R, Nuñez G. The inflammasome: a caspase-1-activation platform that regulates immune responses and disease pathogenesis. Nat Immunol. 2009; 10 (3): 241–7. doi: 10.1038/ni.1703</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Безопасность применения ремдесивира и тоцилизумаба при лечении COVID-19. Безопасность и риск фармакотерапии. 2020; 8 (3):160–162. doi.org/10.30895/2312-7821-2020-8-3-160-162</mixed-citation><mixed-citation xml:lang="en">Safety of Remdesivir and Tocilizumab in COVID-19 Treatment. Safety and Risk of Pharmacotherapy. 2020; 8 (3): 160-162. doi.org/10.30895/2312-7821-2020-8-3-160-162. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Насонов Е. Л. Коронавирусная болезнь-2019 (COVID-19): значение ингибиторов IL-6. Пульмонология. 2020; 30 (5): 629–644. doi: 10.18093/0869-0189-2020-30-5-629-644</mixed-citation><mixed-citation xml:lang="en">Nasonov EL. Coronavirus Disease 2019 (COVID-19): The Importance of IL-6 Inhibitors. Pul’monologiya. 2020; 30 (5): 629–644. doi: 10.18093/0869-0189-2020-30-5-629-644. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Смирнов В. С., Тотолян А. А. Некоторые возможности иммунотерапии при коронавирусной инфекции. Инфекция и иммунитет. 2020; 10 (3): 446–458. doi: 10.15789/2220–7619-SPO-1470</mixed-citation><mixed-citation xml:lang="en">Smirnov VS, Totolyan AA. Some possibilities of immunotherapy for coronavirus infection. Russian Journal of Infection and Immunity. 2020; 10 (3): 446–458. doi: 10.15789/2220–7619-SPO-1470 (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Сташкив В. И., Замятина К. А., Шантаревич М. Ю., Никитина И. В., Кармазановский Г. Г., Ревишвили А. Ш. КТ-семиотика пневмонии у пациентов с COVID-19, получающих терапию тоцилизумабом: обзор зарубежной литературы. Медицинская визуализация. 2020; 24 (2): 96–97. doi.org/10.24835/1607-0763-2020-2-96-97</mixed-citation><mixed-citation xml:lang="en">Stashkiv VI, Zamyatina KA, Shantarevich MYu, Nikitina IV, Kаrmаzаnovsky GG, Revishvili AS. CT findings in patients with COVID-19 pneumonia after treatment with tocilizumab: foreign literature review. Medical Visualization. 2020; 24 (2): 96–104. doi.org/10.24835/1607-0763-2020-2-96-97. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Chen J, Chen R, Huang S, Zu B, Zhang S. Atezolizumab alleviates the immunosuppression induced by PD–L1-positive neutrophils and improves the survival of mice during sepsis. Mol Med Rep. 2021; 23 (2):1. doi: 10.3892/mmr. 2020.11783</mixed-citation><mixed-citation xml:lang="en">Chen J, Chen R, Huang S, Zu B, Zhang S. Atezolizumab alleviates the immunosuppression induced by PD–L1-positive neutrophils and improves the survival of mice during sepsis. Mol Med Rep. 2021; 23 (2):1. doi: 10.3892/mmr.2020.11783</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Bjork P, Bjork A, Vogl T, Stenstrom M, Liberg D, Olsson A, et al. Identification of human S100A9 as a novel target for treatment of autoimmune disease via binding to quinoline-3-carboxamides. PLoS Biol. 2009; 7 (4): e97. doi: 10.1371/journal.pbio.1000097</mixed-citation><mixed-citation xml:lang="en">Bjork P, Bjork A, Vogl T, Stenstrom M, Liberg D, Olsson A, et al. Identification of human S100A9 as a novel target for treatment of autoimmune disease via binding to quinoline-3-carboxamides. PLoS Biol. 2009; 7 (4):e97. doi:10.1371/journal.pbio.1000097</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Bengtsson AA, Sturfelt G, Lood C, Rönnblom L, van Vollenhoven RF, Axelsson B, et al. Pharmacokinetics, tolerability, and preliminary efficacy of paquinimod (ABR-215757), a new quinoline-3-carboxamide derivative: studies in lupus-prone mice and a multicenter, randomized, double-blind, placebocontrolled, repeat-dose, dose-ranging study in p. Arthritis Rheumatol. 2012; 64 (5):1579–88. doi: 10.1002/art.33493</mixed-citation><mixed-citation xml:lang="en">Bengtsson AA, Sturfelt G, Lood C, Rönnblom L, van Vollenhoven RF, Axelsson B, et al. Pharmacokinetics, tolerability, and preliminary efficacy of paquinimod (ABR-215757), a new quinoline-3-carboxamide derivative: studies in lupus-prone mice and a multicenter, randomized, double-blind, placebocontrolled, repeat-dose, dose-ranging study in p. Arthritis Rheumatol. 2012; 64 (5):1579–88. doi:10.1002/art. 33493</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">van Zoelen MA, Vogl T, Foell D, Van Veen SQ, van Till JW, Florquin S, et al. Expression and role of myeloid-related protein-14 in clinical and experimental sepsis. Am J Respir Crit Care Med. 2009; 180 (11): 1098–106. doi: 10.1164/rccm.200810-1552OC</mixed-citation><mixed-citation xml:lang="en">van Zoelen MA, Vogl T, Foell D, Van Veen SQ, van Till JW, Florquin S, et al. Expression and role of myeloid-related protein-14 in clinical and experimental sepsis. Am J Respir Crit Care Med. 2009; 180 (11): 1098–106. doi: 10.1164/rccm.200810-1552OC</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Wang S, Song R, Wang Z, Jing Z, Wang S, Ma J. S100A8/A9 in Inflammation. Front Immunol. 2018; 9: 1298. doi: 10.3389/fimmu.2018.01298</mixed-citation><mixed-citation xml:lang="en">Wang S, Song R, Wang Z, Jing Z, Wang S, Ma J. S100A8/A9 in Inflammation. Front Immunol. 2018; 9:1298. doi:10.3389/fimmu.2018.01298</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
